SMMT

Summit Therapeutics Inc.

SMMT · CIK 1599298 · Annual (10-K) · Last 6 years

Financial Trends

Revenue
20202025
Net Income−$1080M
20202025
Operating CF−$323M
20202025
Free Cash Flow−$324M
20202025

Income Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕
Revenue—$0.0B$0.0B$0.0B$0.0B$0.0B
Cost of Revenue——————
Gross Profit——————
R&D Expense——$0.1B$0.1B$0.1B$0.1B
SG&A Expense——————
Operating Income—$-0.2B$-0.6B$-0.1B$-0.1B$-0.1B
Net Income$-1.1B$-0.2B$-0.6B$-0.1B$-0.1B$-0.1B
EPS (Basic)$-1.44$-0.31$-0.99$-0.41$-0.96$-0.76
EPS (Diluted)$-1.44$-0.31$-0.99$-0.41$-0.96$-0.76

Balance Sheet

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕
Total Assets$0.8B$0.4B$0.2B$0.7B$0.1B$0.1B
Current Assets$0.7B$0.4B$0.2B$0.7B$0.1B$0.1B
Cash & Equivalents$0.2B$0.1B$0.1B$0.3B$0.1B$0.1B
Total Liabilities$0.1B$0.0B$0.1B$0.5B$0.0B$0.0B
Current Liabilities$0.1B$0.0B$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$0.7B$0.4B$0.1B$0.1B$0.1B$0.1B

Cash Flow Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕
Operating Cash Flow$-0.3B$-0.1B$-0.1B$-0.0B$-0.1B$-0.0B
Investing Cash Flow$-0.2B$-0.2B$-0.6B$-0.0B$-0.0B$-0.0B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.6B$0.4B$0.1B$0.6B$0.1B$0.1B
← Companies